LENZ Therapeutics Takes $47M In Series A For Vision Correcting Eye Drops

San Diego-based biopharmaceuticals developer LENZ Therapeutics, a biopharmaceuticals firm which is developing an eye drop which helps treat presbyopia, has raised $47M in a Series A funding round. The company said the funding came from Versant Ventures and RA Capital Management. The company said when its eye drops are used, patient show "rapid and long-lasting" improvements in near vision, with 53% of patients showed three lines or more of reading improvement and 81% showed two lines or more. The eye drops apparently last up to seven hours, with no loss of distance vision. The company said it has named Evert (Eef) Schimmelpennink as President and CEO of the company with the funding.